Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15145778 | 1.00 | HTR2A (0.43) | HTR2AHTR2CHTR2BALDH1A1MAPT | |
| SCHEMBL2600798 | 0.78 | HTR2A (0.37) | HTR2AHTR2CHTR2BALDH1A1MAPT | |
| SCHEMBL25180633 | 0.75 | HTR2A (0.34) | HTR2AHTR2CNOTUMSLC6A2SLC6A4 | |
| SCHEMBL30386978 | 0.75 | MAOA (0.39) | HTR2ANOTUM | |
| SCHEMBL30387994 | 0.75 | HTR2A (0.34) | HTR2AHTR2CNOTUMSLC6A2SLC6A4 | |
| SCHEMBL23505819 | 0.75 | HTR2A (0.34) | HTR2AHTR2CNOTUM | |
| SCHEMBL3554635 | 0.75 | HTR2A (0.34) | HTR2AHTR2CNOTUMSLC6A2SLC6A4 | |
| SCHEMBL19829945 | 0.75 | HTR2A (0.43) | HTR2AHTR2CNOTUM | |
| SCHEMBL3167798 | 0.75 | MAOA (0.39) | HTR2ANOTUM | |
| SCHEMBL19829938 | 0.75 | HTR2A (0.43) | HTR2AHTR2CNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1089963-B1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE | SMITHKLINE BEECHAM PLC (GB) | 2004-06-16 | — | — | EP | claimed |
| US-6458779-B1 | TREATMENT OF CONDITIONS ASSOCIATED WITH EXCESS PRODUCTION OF SOLUBLE CD23 (S-CD23) SUCH AS AUTOIMMUNE DISEASE AND ALLERGY. THE COMPOUNDS OF THE INVENTION ARE ALSO INHIBITORS OF THE RELEASE OF TUMOUR NECROSIS FACTOR (TNF). | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-01 | — | — | US | claimed |
| WO-2023192375-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230174492-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230141809-A1 | QUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-05-11 | — | — | US | disclosed |
| WO-2022260441-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2022-12-15 | — | — | WO | disclosed |
| WO-2021242844-A1 | GRK2 INHIBITORS AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| US-11077090-B2 | Compounds and compositions and uses thereof | SUNOVION PHARMACEUTICALS INC. (MA) | 2021-08-03 | — | — | US | disclosed |
| WO-2018023070-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| US-20180028492-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | PGI DRUG DISCOVERY LLC | 2018-02-01 | — | — | US | disclosed |
| WO-2008011392-A2 | PROLINE UREA CCR1 ANTAGONISTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR INFLAMMATION | LIGAND PHARMACUETICALS INCORPORATED (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| EP-0179377-B1 | PROCESS FOR THE PREPARATION OF 1-ALKOXYISOCHROMANES, AND 1-ALKOXY ALKYLISOCHROMANES | BASF Aktiengesellschaft (DE) | 1988-01-20 | — | — | EP | disclosed |
| EP-0179377-A1 | Process for the preparation of 1-alkoxyisochromanes, and 1-alkoxy alkylisochromanes | BASF Aktiengesellschaft (DE) | 1986-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | HTR2A 3273/4885HTR2C 3674/4885HTR2B 3072/4885 |
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | HTR2A 1261/4885HTR2C 2656/4885HTR2B 1124/4885 |
| US-11077090-B2 | Compounds and compositions and uses thereof | ACHE, CHAT, MAOB | HTR2A 199/4885HTR2C 196/4885HTR2B 146/4885 |
| US-20180028492-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ACHE, CHAT, MAOB | HTR2A 199/4885HTR2C 196/4885HTR2B 146/4885 |
| US-20230141809-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, QTRT2 | HTR2A 1252/4885HTR2C 852/4885HTR2B 1050/4885 |
| US-20230174492-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | H1-5, H1-10, H1-0 | HTR2A 827/4885HTR2C 1437/4885HTR2B 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.